(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Celcuity, Restoration Hardware Holdings, and Dogness.

The three biggest losers today are CohBar, MicroStrategy, and Dare Bioscience.

Winners today

1. Celcuity (CELC) – 18.94%

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

NASDAQ ended the session with Celcuity rising 18.94% to $21.60 on Friday, after two consecutive sessions in a row of gains. NASDAQ slid 0.12% to $16,379.46, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Celcuity has a trailing twelve months EPS of $-2.74.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -46.63%.

Yearly Top and Bottom Value

Celcuity’s stock is valued at $21.60 at 17:32 EST, under its 52-week high of $22.19 and way higher than its 52-week low of $8.39.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is a negative 40% and a negative 21.2%, respectively.

More news about Celcuity.

2. Restoration Hardware Holdings (RH) – 17.26%

RH, together with its subsidiaries, operates as a retailer in the home furnishings and operates under RH Galleries and RH brand names in the District of Columbia and Canada, as well as Waterworks showrooms throughout the United States and the United Kingdom. It offers products in various categories, including furniture, lighting, textiles, bathware, décor, outdoor and garden, and child and teen furnishings. The company provides its products through its retail galleries; online through rh.com, rhbabyandchild.com, rhteen.com, and rhmodern.com, as well as waterworks.com, and Source Books, a series of catalogs. The company was formerly known as Restoration Hardware Holdings, Inc. and changed its name to RH in January 2017. RH was incorporated in 2011 and is headquartered in Corte Madera, California.

NYSE ended the session with Restoration Hardware Holdings jumping 17.26% to $348.26 on Friday, after two sequential sessions in a row of gains. NYSE jumped 0.31% to $18,312.67, after two successive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Restoration Hardware Holdings has a trailing twelve months EPS of $9.47.

PE Ratio

Restoration Hardware Holdings has a trailing twelve months price to earnings ratio of 36.78. Meaning, the purchaser of the share is investing $36.78 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 46.44%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 13.6%, now sitting on 3.06B for the twelve trailing months.

More news about Restoration Hardware Holdings.

3. Dogness (DOGZ) – 16.67%

Dogness (International) Corporation, through its subsidiaries, designs, manufactures, and sells fashionable products for dogs and cats worldwide. The company provides pet leashes, pet collars, pet harnesses, and retractable leashes, as well as lanyards; gift suspenders, pet belt ribbons, laces, elastic belts, computer jacquard ribbons, and high-grade textile laces; mouth covers and pet charms; climbing hooks; and intelligent pet products, such as app-controlled pet feeders, pet water fountains, and smart pet toys, as well as pet shampoos. It also offers ribbon dyeing service and pet grooming services. It offers its products to wholesalers and retailers. The company was founded in 2003 and is headquartered in Dongguan, the People's Republic of China.

NASDAQ ended the session with Dogness rising 16.67% to $5.81 on Friday while NASDAQ fell 0.12% to $16,379.46.

Earnings Per Share

As for profitability, Dogness has a trailing twelve months EPS of $-3.6.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -9.05%.

More news about Dogness.

4. Matterport
(MTTR) – 15.9%

Matterport, Inc., a spatial data company, focuses on digitization and datafication in the United States and internationally. The company offers Matterport Capture Services, a fully managed solution for enterprise subscribers; Matterport Pro3, a 3D camera that scans properties; Matterport Pro2, a 3D camera that captures spaces; LEICA BLK360, a device to create digital twins; Smartphone Capture, a smartphone capture solution for both iOS and Android; and 360 Cameras. It also provides Matterport Axis, a motor-mount accessory for smartphone. The company serves its products in residential and commercial real estate, facilities management and retail, AEC, insurance and repair, and travel and hospitality markets. Matterport, Inc. is headquartered in Sunnyvale, California.

NASDAQ ended the session with Matterport
jumping 15.9% to $2.26 on Friday while NASDAQ dropped 0.12% to $16,379.46.

Earnings Per Share

As for profitability, Matterport
has a trailing twelve months EPS of $-0.66.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -35.77%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Matterport
‘s stock is considered to be oversold (<=20).

Earnings Before Interest, Taxes, Depreciation, and Amortization

Matterport
‘s EBITDA is 1.42.

Volatility

Matterport
‘s last week, last month’s, and last quarter’s current intraday variation average was a positive 2.39%, a negative 0.44%, and a positive 3.20%.

Matterport
‘s highest amplitude of average volatility was 3.13% (last week), 3.09% (last month), and 3.20% (last quarter).

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 57.1% and 57.1%, respectively.

More news about Matterport
.

5. Matterport
(MTTR) – 15.9%

Matterport, Inc., a spatial data company, focuses on digitization and datafication in the United States and internationally. The company offers Matterport Capture Services, a fully managed solution for enterprise subscribers; Matterport Pro3, a 3D camera that scans properties; Matterport Pro2, a 3D camera that captures spaces; LEICA BLK360, a device to create digital twins; Smartphone Capture, a smartphone capture solution for both iOS and Android; and 360 Cameras. It also provides Matterport Axis, a motor-mount accessory for smartphone. The company serves its products in residential and commercial real estate, facilities management and retail, AEC, insurance and repair, and travel and hospitality markets. Matterport, Inc. is headquartered in Sunnyvale, California.

NASDAQ ended the session with Matterport
rising 15.9% to $2.26 on Friday while NASDAQ dropped 0.12% to $16,379.46.

Earnings Per Share

As for profitability, Matterport
has a trailing twelve months EPS of $-0.66.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -35.77%.

Volume

Today’s last reported volume for Matterport
is 9842550 which is 300.61% above its average volume of 2456860.

Yearly Top and Bottom Value

Matterport
‘s stock is valued at $2.26 at 17:32 EST, way under its 52-week high of $3.78 and way above its 52-week low of $1.84.

More news about Matterport
.

6. Nikola (NKLA) – 14.4%

Nikola Corporation operates as a technology innovator and integrator that develops energy and transportation solutions in the United States and internationally. The company operates in truck and energy units. It commercializes battery electric vehicles (BEV) and hydrogen fuel cell electric vehicles (FCEV) to the trucking sector. In addition, it develops a network of hydrogen fueling stations; and offers BEV charging solutions for its FCEV and BEV customers, as well as other third-party customers. Further, its products include Nikola Tre Class 8 truck and the Nikola's Class 8 FCEV. Additionally, the company assembles, integrates, and commissions its vehicles in collaboration with its business partners and suppliers. Nikola Corporation founded in 2015 and is headquartered in Phoenix, Arizona.

NASDAQ ended the session with Nikola jumping 14.4% to $1.04 on Friday while NASDAQ fell 0.12% to $16,379.46.

Earnings Per Share

As for profitability, Nikola has a trailing twelve months EPS of $-1.21.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -138.82%.

Previous days news about Nikola

• Is nikola (nkla) stock outpacing its auto-tires-trucks peers this year?. According to Zacks on Thursday, 28 March, "To break things down more, Nikola belongs to the Automotive – Domestic industry, a group that includes 20 individual companies and currently sits at #57 in the Zacks Industry Rank. ", "This means that Nikola is performing better than its sector in terms of year-to-date returns."

More news about Nikola.

7. Check-Cap Ltd. (CHEK) – 13.09%

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.

NASDAQ ended the session with Check-Cap Ltd. rising 13.09% to $3.11 on Friday, after three successive sessions in a row of gains. NASDAQ dropped 0.12% to $16,379.46, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Check-Cap Ltd. has a trailing twelve months EPS of $-3.01.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -48.74%.

More news about Check-Cap Ltd..

8. Equillium (EQ) – 12.14%

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

NASDAQ ended the session with Equillium rising 12.14% to $2.31 on Friday, following the last session’s upward trend. NASDAQ fell 0.12% to $16,379.46, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Equillium has a trailing twelve months EPS of $-0.38.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -48.92%.

Moving Average

Equillium’s value is way above its 50-day moving average of $1.94 and way above its 200-day moving average of $1.02.

More news about Equillium.

9. Eloxx Pharmaceuticals (ELOX) – 11.11%

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

NASDAQ ended the session with Eloxx Pharmaceuticals jumping 11.11% to $1.00 on Friday, after two sequential sessions in a row of gains. NASDAQ dropped 0.12% to $16,379.46, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, Eloxx Pharmaceuticals has a trailing twelve months EPS of $-8.88.

Volume

Today’s last reported volume for Eloxx Pharmaceuticals is 13861 which is 37.97% above its average volume of 10046.

More news about Eloxx Pharmaceuticals.

10. Corbus Pharmaceuticals Holdings (CRBP) – 10.32%

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

NASDAQ ended the session with Corbus Pharmaceuticals Holdings rising 10.32% to $39.24 on Friday, following the last session’s upward trend. NASDAQ fell 0.12% to $16,379.46, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Corbus Pharmaceuticals Holdings has a trailing twelve months EPS of $-10.31.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -341.98%.

Yearly Top and Bottom Value

Corbus Pharmaceuticals Holdings’s stock is valued at $39.24 at 17:32 EST, way below its 52-week high of $49.87 and way above its 52-week low of $3.03.

Moving Average

Corbus Pharmaceuticals Holdings’s value is way above its 50-day moving average of $28.68 and way above its 200-day moving average of $11.91.

Volume

Today’s last reported volume for Corbus Pharmaceuticals Holdings is 234856 which is 75.24% below its average volume of 948908.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 74.3% and 41.5%, respectively.

More news about Corbus Pharmaceuticals Holdings.

Losers Today

1. CohBar (CWBR) – -11.99%

CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.

NASDAQ ended the session with CohBar dropping 11.99% to $0.88 on Friday, following the last session’s downward trend. NASDAQ fell 0.12% to $16,379.46, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, CohBar has a trailing twelve months EPS of $-4.37.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -83.97%.

Moving Average

CohBar’s worth is higher than its 50-day moving average of $0.83 and way under its 200-day moving average of $1.81.

Volume

Today’s last reported volume for CohBar is 593 which is 81.51% below its average volume of 3208.

More news about CohBar.

2. MicroStrategy (MSTR) – -11.18%

MicroStrategy Incorporated provides artificial intelligence-powered enterprise analytics software and services in the United States, Europe, the Middle East, Africa, and internationally. It offers MicroStrategy ONE, which provides non-technical users with the ability to directly access novel and actionable insights for decision-making; and MicroStrategy Cloud for Government service, which offers always-on threat monitoring that meets the rigorous technical and regulatory needs of governments and financial institutions. The company also provides MicroStrategy Support that helps customers achieve their system availability and usage goals through highly responsive troubleshooting and assistance; MicroStrategy Consulting, which provides architecture and implementation services to help customers realize their desired results; and MicroStrategy Education that offers free and paid learning options. In addition, it engages in the development of bitcoin. The company offers its services through direct sales force and channel partners. It serves the U.S. government, state and local governments, and government agencies, as well as a range of industries, including retail, banking, technology, manufacturing, insurance, consulting, healthcare, telecommunications, and the public sector. The company was incorporated in 1989 and is headquartered in Tysons Corner, Virginia.

NASDAQ ended the session with MicroStrategy dropping 11.18% to $1,704.56 on Friday while NASDAQ fell 0.12% to $16,379.46.

Earnings Per Share

As for profitability, MicroStrategy has a trailing twelve months EPS of $26.48.

PE Ratio

MicroStrategy has a trailing twelve months price to earnings ratio of 64.37. Meaning, the purchaser of the share is investing $64.37 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 48.17%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 6.1%, now sitting on 496.26M for the twelve trailing months.

Sales Growth

MicroStrategy’s sales growth is 1.7% for the ongoing quarter and negative 3.1% for the next.

Yearly Top and Bottom Value

MicroStrategy’s stock is valued at $1,704.56 at 17:32 EST, way above its 52-week high of $1,451.73.

More news about MicroStrategy.

3. Dare Bioscience (DARE) – -10.71%

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy. The company's Phase I-ready products are DARE-VVA1, a proprietary formulation of tamoxifen for intravaginal to treat vulvar vaginal atrophy in women with hormone-receptor positive breast cancer; DARE-PDM1, a proprietary hydrogel formulation of diclofenac, a nonsteroidal anti-inflammatory drug, for vaginal administration as a treatment for dysmenorrhea; DARE-204 and DARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-GML, an intravaginally-delivered potential multi-target antimicrobial agent formulated with glycerol monolaurate; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

NASDAQ ended the session with Dare Bioscience dropping 10.71% to $0.49 on Friday while NASDAQ dropped 0.12% to $16,379.46.

Earnings Per Share

As for profitability, Dare Bioscience has a trailing twelve months EPS of $-0.48.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -341.28%.

Volume

Today’s last reported volume for Dare Bioscience is 539524 which is 29.56% above its average volume of 416403.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Dare Bioscience’s EBITDA is -3.86.

Yearly Top and Bottom Value

Dare Bioscience’s stock is valued at $0.49 at 17:32 EST, way under its 52-week high of $1.10 and way above its 52-week low of $0.27.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 47.4% and 33.3%, respectively.

More news about Dare Bioscience.

4. Canopy Growth (CGC) – -9.63%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth dropping 9.63% to $8.63 on Friday, after two consecutive sessions in a row of losses. NASDAQ fell 0.12% to $16,379.46, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-15.67.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -121.56%.

More news about Canopy Growth.

5. FibroGen (FGEN) – -8.91%

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

NASDAQ ended the session with FibroGen sliding 8.91% to $2.35 on Friday while NASDAQ slid 0.12% to $16,379.46.

Earnings Per Share

As for profitability, FibroGen has a trailing twelve months EPS of $-2.92.

Revenue Growth

Year-on-year quarterly revenue growth declined by 21%, now sitting on 147.75M for the twelve trailing months.

More news about FibroGen.

6. Clearside Biomedical (CLSD) – -8.38%

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

NASDAQ ended the session with Clearside Biomedical sliding 8.38% to $1.53 on Friday while NASDAQ fell 0.12% to $16,379.46.

Earnings Per Share

As for profitability, Clearside Biomedical has a trailing twelve months EPS of $-0.53.

Sales Growth

Clearside Biomedical’s sales growth is 14400% for the ongoing quarter and negative 42% for the next.

More news about Clearside Biomedical.

7. CleanSpark (CLSK) – -8.22%

CleanSpark, Inc. engages in bitcoin mining operations. It develops sustainable infrastructure for Bitcoin, a tool for financial independence and inclusion. The company was formerly known as Stratean Inc. and changed its name to CleanSpark, Inc. in November 2016. CleanSpark, Inc. was incorporated in 1987 and is headquartered in Henderson, Nevada.

NASDAQ ended the session with CleanSpark falling 8.22% to $21.21 on Friday while NASDAQ slid 0.12% to $16,379.46.

Earnings Per Share

As for profitability, CleanSpark has a trailing twelve months EPS of $-0.69.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.24%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 165.2%, now sitting on 214.38M for the twelve trailing months.

Moving Average

CleanSpark’s value is way above its 50-day moving average of $14.84 and way above its 200-day moving average of $8.14.

Earnings Before Interest, Taxes, Depreciation, and Amortization

CleanSpark’s EBITDA is 18.66.

Volume

Today’s last reported volume for CleanSpark is 42202900 which is 17.27% above its average volume of 35987600.

More news about CleanSpark.

8. SNDL Inc. (SNDL) – -8.03%

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

NASDAQ ended the session with SNDL Inc. dropping 8.03% to $2.01 on Friday, following the last session’s downward trend. NASDAQ slid 0.12% to $16,379.46, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, SNDL Inc. has a trailing twelve months EPS of $-0.48.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -17.6%.

More news about SNDL Inc..

9. Fortress Biotech (FBIO) – -7.83%

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in New York, New York.

NASDAQ ended the session with Fortress Biotech dropping 7.83% to $2.00 on Friday while NASDAQ dropped 0.12% to $16,379.46.

Earnings Per Share

As for profitability, Fortress Biotech has a trailing twelve months EPS of $-11.34.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -414.52%.

Yearly Top and Bottom Value

Fortress Biotech’s stock is valued at $2.00 at 17:32 EST, way under its 52-week high of $12.75 and way higher than its 52-week low of $1.24.

More news about Fortress Biotech.

10. Aurora Cannabis (ACB) – -7.58%

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

NYSE ended the session with Aurora Cannabis dropping 7.58% to $4.39 on Friday while NYSE rose 0.31% to $18,312.67.

Earnings Per Share

As for profitability, Aurora Cannabis has a trailing twelve months EPS of $-58.28.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -102.67%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 30.4%, now sitting on 225.18M for the twelve trailing months.

Moving Average

Aurora Cannabis’s worth is way higher than its 50-day moving average of $0.47 and way above its 200-day moving average of $0.54.

More news about Aurora Cannabis.

Stay up to date with our winners and losers daily report